SynthesisNeuropsychology review2021
Antisaccades in Parkinson's Disease: A Meta-Analysis.
Synthesis in Neuropsychology review, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06899022 (Investigating the Role of Attention in Perceptual and Cognitive Consequences of Parkinson's Disease), which is not on this map. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating the Role of Attention in Perceptual and Cognitive Consequences of Parkinson's Disease
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effectiveness and safety of theta burst stimulation for Parkinson's disease: an updated systematic review and meta-analysis of randomized parallel-group controlled trials.Frontiers in neurology · 2026Pooled it
- Recent advances (2022-2024) in eye-tracking for Parkinson's disease: a promising tool for diagnosing and monitoring symptoms.Frontiers in aging neuroscience · 2025Pooled it
- Oculomotor atypicalities in motor neurone disease: a systematic review.Frontiers in neuroscience · 2024Pooled it
- Naturalistic Eye Movement Tasks in Parkinson's Disease: A Systematic Review.Journal of Parkinson's disease · 2024Pooled it
- Theta Oscillations, Oculomotor Processing, and Neural Synchronization: A Review.Brain sciences · 2026Review
- iPad Eye Tracking Reproduces Clinical Grade Oculomotor Differences in Parkinson's Disease.NPJ digital medicine · 2026Article
- VR-based quantitative oculomotor analysis and association with regional brain atrophy in MSA.Journal of Parkinson's disease · 2026Article
- Eye tracking as a digital biomarker in neurodegenerative diseases.Journal of neurology · 2026Review
- Computational Modeling of Parkinson's Disease Across Scales: From Mechanisms to Biomarkers, Drug Discovery, and Personalized Therapies.Brain sciences · 2026Review
- Towards scalable screening for the early detection of Parkinson's disease: validation of an iPad-based eye movement assessment system against a clinical-grade eye tracker.NPJ Parkinson's disease · 2025Article
- ABBA Letter Alternation: A telehealth inspired measure of executive functioning/inhibitory control.The Clinical neuropsychologist · 2025Article
- Effects of Different Numbers of Trials on Saccadometry Test Results.Brain and behavior · 2025Article
- An Evaluation of Test-Retest Reliability of the Saccadometry Test.Journal of the American Academy of Audiology · 2025Article
- Metabolomics in Parkinson's Disease and Correlation with Disease State.Metabolites · 2025Review
- Diagnosis of Parkinson's disease by eliciting trait-specific eye movements in multi-visual tasks.Journal of translational medicine · 2025Article
- Quantitative comparison of a mobile, tablet-based eye-tracker and two stationary, video-based eye-trackers.Behavior research methods · 2025Article
- Multimodal oculomotor assessment reveals prodromal markers of Parkinson's disease in non-manifesting LRRK2 G2019S mutation carriers.NPJ Parkinson's disease · 2024Article
- Eyes as a window to brain pathology in parkinson's disease: a narrative review.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Inhibitory control and working memory using saccadic eye movements in primary glaucoma.Attention, perception & psychophysics · 2024Article
- Digital biomarkers for precision diagnosis and monitoring in Parkinson's disease.NPJ digital medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The usefulness of eye-tracking tasks as potential biomarkers for motor or cognitive disease burden in Parkinson's disease (PD) has been subject of debate for many years. Several studies suggest that the performance in the antisaccade task may be altered in patients with PD and associated with motor disease severity or executive dysfunction. In this meta-analysis, random effects models were used to synthesize the existing evidence on antisaccade error rates and latency in PD. Furthermore, meta-regressions were performed to assess the role of motor and cognitive disease severity, dopaminergic medication and methodological factors. Additionally, the impact of acute levodopa administration and activation of deep brain stimulation was evaluated in two separate sub-analyses.This meta-analysis confirms that antisaccade latency and error rate are significantly increased in PD. Disease duration, Unified Parkinson's disease rating scale score and Hoehn and Yahr stage mediate the effect of PD on antisaccade latency with higher motor burden being associated with increased antisaccade latency.Acute administration of levodopa had no significant effects on antisaccade performance in a small number of eligible studies. Deep brain stimulation in the subthalamic nucleus, on the other hand, may alter the speed accuracy trade-off supporting an increase of impulsivity following deep brain stimulation in PD.According to the results of the meta-analysis, antisaccade latency may provide a potential marker for disease severity and progression in PD which needs further confirmation in longitudinal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.